Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, United Kingdom.
Respir Med. 2011 Oct;105(10):1413-21. doi: 10.1016/j.rmed.2011.05.012.
Pulmonary-renal syndromes are a group of disorders characterised by necrotising glomerulonephritis and pulmonary haemorrhage. Small vessel systemic vasculitis is the most common cause of pulmonary-renal syndromes presenting to respiratory physicians. Rarer causes include systemic lupus erythematosus and connective tissue diseases though severe pneumonia or cardiac failure may mimic their presentation. Some forms of small vessel vasculitides have a predilection for the pulmonary and renal vascular beds and if left untreated can result in fulminant organ failure. Whilst the aetiology of these syndromes remains unclear, much is known about the disease mechanisms including the pathogenic role of autoantibodies, immune-complex mediated inflammation and microangiopathic in-situ thrombosis. Despite established treatments achieving successful remission induction, patient tolerability and side effect profiles have limited their use which has led to searches for more targeted treatments. Consequently newer biological therapies have gained wider acceptance despite little being known about their long term safety and efficacy. The European Vasculitis Study Group (EUVAS) have recently formulated guidelines to provide consensus on diagnosis and management in this area and work to define survival rates in these conditions with longer term follow-up studies is ongoing. This review summarises the current aetiopathogenesis thought to underlie these complex diseases, the diagnostic definitions and classification criteria currently in use and the evidence base for modern therapies. Though unusual for respiratory specialists to coordinate overall management of these patients, an update on their current management is regarded as important to their practice given the recently changing trends in treatments.
肺肾综合征是一组以坏死性肾小球肾炎和肺出血为特征的疾病。小血管系统性血管炎是最常见的导致肺肾综合征的原因,也是呼吸科医生最常见的病因。更罕见的病因包括系统性红斑狼疮和结缔组织疾病,但严重肺炎或心力衰竭可能会模仿其表现。某些形式的小血管血管炎倾向于肺部和肾脏血管床,如果不治疗,可能会导致暴发性器官衰竭。尽管这些综合征的病因仍不清楚,但我们对疾病机制有了很多了解,包括自身抗体的致病作用、免疫复合物介导的炎症和原位微血管血栓形成。尽管已经确定了有效的治疗方法来诱导缓解,但患者的耐受性和副作用特征限制了其使用,这导致了对更有针对性治疗方法的探索。因此,尽管对这些新型生物疗法的长期安全性和疗效知之甚少,但它们仍得到了更广泛的认可。欧洲血管炎研究组 (EUVAS) 最近制定了指南,就该领域的诊断和管理提供了共识,并努力通过长期随访研究来确定这些疾病的生存率。这篇综述总结了目前认为与这些复杂疾病有关的发病机制、目前使用的诊断定义和分类标准,以及现代治疗方法的证据基础。尽管对呼吸科专家来说,协调这些患者的整体管理是不常见的,但鉴于治疗方法最近发生的变化,更新他们的当前治疗方法被认为对他们的实践很重要。